National Guideline Clearinghouse | Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.

full-text ►

National Guideline Clearinghouse | Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.



National Clinical Guideline Centre

Guideline Title

Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.

Bibliographic Source(s)

National Clinical Guideline Centre. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London (UK): National Institute for Health and Care Excellence (NICE); 2014 Jul. 50 p. (Clinical guideline; no. 181).

Guideline Status

This is the current release of the guideline.

This guideline updates previous versions:

National Collaborating Centre for Primary Care. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 May. 37 p. (Clinical guideline; no. 67).

National Institute for Health and Clinical Excellence (NICE). Statins for the prevention of cardiovascular events. London (UK): National Institute for Health and Clinical Excellence (NICE); 2006 Jan. 45 p. (Technology appraisal guidance; no. 94).

This guideline meets NGC's 2013 (revised) inclusion criteria.